The study provided information on whether the benefits of initiating ART at CD4+ cell counts above 500 cells/mm3 outweigh the risks. The international randomized trial determined that starting ART early reduces the occurrence of serious morbidity and mortality. START began enrolment in April 2009 and involved 35 countries including Nigeria with IHVN anchoring the study in the country.
The study provided information on whether the benefits of initiating ART at CD4+ cell counts above 500 cells/mm3 outweigh the risks. The international randomized trial determined that starting ART early reduces the occurrence of serious morbidity and mortality. START began enrolment in April 2009 and involved 35 countries including Nigeria with IHVN anchoring the study in the country.